Similar response rates and survival with PARP inhibitors for patients with solid tumors harboring somatic versus Germline BRCA mutations: a Meta-analysis and systematic review
dc.contributor.author | Mohyuddin, Ghulam Rehman | |
dc.contributor.author | Aziz, Muhammad | |
dc.contributor.author | Britt, Alec | |
dc.contributor.author | Wade, Lee | |
dc.contributor.author | Sun, Weijing | |
dc.contributor.author | Baranda, Joaquina | |
dc.contributor.author | Al-Rajabi, Raed | |
dc.contributor.author | Saeed, Anwaar | |
dc.contributor.author | Kasi, Anup | |
dc.date.accessioned | 2020-09-15T15:01:15Z | |
dc.date.available | 2020-09-15T15:01:15Z | |
dc.date.issued | 2020-06-03 | |
dc.identifier.citation | Mohyuddin, G.R., Aziz, M., Britt, A. et al. Similar response rates and survival with PARP inhibitors for patients with solid tumors harboring somatic versus Germline BRCA mutations: a Meta-analysis and systematic review. BMC Cancer 20, 507 (2020). https://doi.org/10.1186/s12885-020-06948-5 | en_US |
dc.identifier.uri | http://hdl.handle.net/1808/30736 | |
dc.description | A grant from the One-University Open Access Fund at the University of Kansas was used to defray the author's publication fees in this Open Access journal. The Open Access Fund, administered by librarians from the KU, KU Law, and KUMC libraries, is made possible by contributions from the offices of KU Provost, KU Vice Chancellor for Research & Graduate Studies, and KUMC Vice Chancellor for Research. For more information about the Open Access Fund, please see http://library.kumc.edu/authors-fund.xml. | en_US |
dc.description.abstract | Background PARP inhibitors (PARPi) have recently been approved for various malignancies based on the results of several clinical trials. However, these trials have mostly recruited patients with germline BRCA mutations, and it is unclear whether PARPi have similar efficacy in patients with somatic BRCA mutations. Our study aimed to determine the efficacy of PARPi in patients with somatic BRCA mutations.Methods We performed a meta-analysis comparing overall response rate to PARPi in patients harboring somatic versus germline BRCA mutations. We looked at studies including somatic and germline mutations in BRCA patients that received PARPi.Results After screening and removing duplicates, 18 studies met our criteria for including both somatic and germline BRCA mutations. Only 8 studies reported response rates for both somatic and germline BRCA mutations. In those studies, 24 out of 43 patients with somatic BRCA mutations (55.8%), and 69 out of 157 (43.9%) patients with germline BRCA patients had a response to therapy to PARPi. This difference was not statistically significant (p = 0.399). In all five studies that reported progression-free survival, there was no obvious difference in outcomes between somatic versus germline BRCA patients, however a precise statistical analysis could not be performed.Conclusion Our meta-analysis and systematic review of the literature indicates similar response rates of PARPi therapy in patients with somatic and germline BRCA mutations. Investigation of use of PARPi therapy in a broader patient population, and the inclusion of somatic BRCA mutations in further clinical trials is paramount in improving therapeutic options for our patients. | en_US |
dc.publisher | BioMed Central | en_US |
dc.rights | © The Author(s). 2020 Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data. | en_US |
dc.rights.uri | http://creativecommons.org/licenses/by/4.0/ | en_US |
dc.subject | PARP inhibitors | en_US |
dc.subject | BRCA | en_US |
dc.subject | Somatic | en_US |
dc.subject | Germline | en_US |
dc.subject | Meta-analysis | en_US |
dc.title | Similar response rates and survival with PARP inhibitors for patients with solid tumors harboring somatic versus Germline BRCA mutations: a Meta-analysis and systematic review | en_US |
dc.type | Article | en_US |
kusw.kuauthor | Mohyuddin, Ghulam Rehman | |
kusw.kuauthor | Britt, Alec | |
kusw.kuauthor | Sun, Weijing | |
kusw.kuauthor | Baranda, Joaquina | |
kusw.kuauthor | Al-Rajabi, Raed | |
kusw.kuauthor | Saeed, Anwaar | |
kusw.kuauthor | Kasi, Anup | |
kusw.kudepartment | Internal Medicine | en_US |
kusw.kudepartment | Oncology | en_US |
dc.identifier.doi | 10.1186/s12885-020-06948-5 | en_US |
dc.identifier.orcid | https://orcid.org/0000-0002-4305-5701 | en_US |
kusw.oaversion | Scholarly/refereed, publisher version | en_US |
kusw.oapolicy | This item meets KU Open Access policy criteria. | en_US |
dc.rights.accessrights | openAccess | en_US |
Files in this item
This item appears in the following Collection(s)
Except where otherwise noted, this item's license is described as: © The Author(s). 2020 Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.